Akshay K. Vaishnaw
Net Worth
Last updated:
What is Akshay K. Vaishnaw net worth?
The estimated net worth of Dr. Akshay K. Vaishnaw is at least $77,471,500 as of 4 Aug 2023. He owns shares worth $10,228,259 as insider, has earned $53,073,241 from insider trading and has received compensation worth at least $14,170,000 in Alnylam Pharmaceuticals, Inc..
What is the salary of Akshay K. Vaishnaw?
Dr. Akshay K. Vaishnaw salary is $1,090,000 per year as Pres of R&D in Alnylam Pharmaceuticals, Inc..
How old is Akshay K. Vaishnaw?
Dr. Akshay K. Vaishnaw is 62 years old, born in 1963.
What stocks does Akshay K. Vaishnaw currently own?
As insider, Dr. Akshay K. Vaishnaw owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | Pres of R&D | 22,774 | $449.12 | $10,228,259 |
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Akshay K. Vaishnaw insider trading
Alnylam Pharmaceuticals, Inc.
Dr. Akshay K. Vaishnaw has made 54 insider trades between 2012-2023, according to the Form 4 filled with the SEC. Most recently he sold 771 units of ALNY stock worth $142,404 on 4 Aug 2023.
The largest trade he's ever made was exercising 88,554 units of ALNY stock on 14 Mar 2018. As of 4 Aug 2023 he still owns at least 22,774 units of ALNY stock.
Alnylam Pharmaceuticals key executives
Alnylam Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Akshay K. Vaishnaw (62) Pres of R&D
- Dr. John M. Maraganore M.D., Ph.D. (62) Chief Executive Officer & Executive Director
- Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB (62) Pres, Chief Operating Officer & Director
- Mr. Jeffrey V. Poulton M.B.A. (57) Chief Financial Officer & Executive Vice President
- Mr. Michael W. Bonney B.A. (67) Executive Chairman